May 2026

# TULLY LILLIS

50 California St., SUITE 1900
San Francisco, CA 94111
DIRECT: +1 510 285 1225
TLILLIS@COMPASSLEXECON.COM

Tully Lillis is a Senior Vice President with Compass Lexecon and Co-Head of the San Francisco Bay Area office, CA. Mr. Lillis specializes in applying economic and quantitative analysis to areas of competition and antitrust and has extensive experience leading engagement teams in support of experts on a wide variety of complex litigation and regulatory matters. Mr. Lillis has substantial and wide-ranging experience consulting in the healthcare sector for private companies and Federal agencies. Mr. Lillis has led teams in support of expert witnesses on major litigation and regulatory matters related to pharmaceutical product hopping, reverse payment settlements, delayed generic entry, price fixing, PBM formulary and rebating practices, life science instrument manufacturing, bundled product discounts, and predatory pricing. Mr. Lillis has deep institutional knowledge and familiarity of the competitive dynamics, industry data, and regulatory framework within the space and has co-authored and presented economic studies in the healthcare space before US antitrust authorities.

In addition to pharmaceutical and healthcare related matters, Mr. Lillis's has led analyses of proposed mergers and of the competitive effects of business practices in a variety of industries including digital marketplaces, consumer payment systems, aircraft manufacturing, collegiate and professional sports, energy generation, and electronics.

## PROFESSIONAL EXPERIENCE

Compass Lexecon, Oakland, CA, 2011-present

| | |
|---|---|
| Senior *Vice President,* | 2025 - Present |
| *Vice President,* | 2022 - 2025 |
| *Senior Economist,* | 2019 - 2022 |
| *Economist*, | 2014 - 2019 |
| *Senior Analyst*, | 2013 - 2014 |
| *Analyst*, | 2011 – 2013 |

Fisher Investments, San Mateo, CA, 2011

*Marketing Associate*, 2011
*Junior Associate*, 2011

## EDUCATION

*BA in Economics (High Distinction)*, University of California, Berkeley, 2011

## SELECTED CONSULTING EXPERIENCE (PREVIOUS 10 YEARS)

Avadel Pharmaceuticals v. Jazz Pharmaceuticals: Consultant to Avadel Pharmaceuticals in case involving the delay of its product to market due to alleged improper listing of Orange Book patents by competing firm (Liability and Damages), 2024-2025. Named GCR matter Litigation of the Year (Non-Cartel Prosecution) at the 2026 GCR Awards.

Consultant to generic pharmaceutical manufacturer in a case involving the delay of its product to market due to alleged sham litigation (Liability and Damages), 2023-2024.

## SELECTED CONSULTING EXPERIENCE (PREVIOUS 10 YEARS, CONT'D)

Consultant to joint defendants in a case involving broad allegations of generic pharmaceutical collusion and price fixing (Liability), 2023-2024.

Consultant to Class Plaintiffs in a case involving delayed generic entry, product hopping, and patent extension strategies for HIV medications (Liability), 2021-2023.

Consultant to Mylan in various cases involving allegations that Mylan entered rebate agreements with pharmacy benefit managers ("PBMs") for favorable and exclusive formulary placement of Mylan's EpiPen Auto-injector that had the effect of excluding Sanofi's rival product, Auvi-Q, from the market and inflated prices to consumers (Liability), 2018-2022.

Co-authored white paper and presented economic analysis to FTC on behalf of manufacturer of life science and clinical instruments concerning its proposed acquisition of a pre-market start-up, 2021-2022.

Consultant to medical device manufacturer in a case alleging its sales relationships included impermissible restraints on competition (Liability), 2021.

Consultant to manufacturer of life science and clinical instruments in a case alleging attempted monopolization through prior firm acquisitions and alleging monopolization in certain upstream IP markets (Liability and Damages), 2020-2021.

Consultant to Branded pharmaceutical manufacturer in a case involving alleged agreements to delay generic entry while it moved the market to an alternate formulation of its blockbuster drug (Damages), 2020.

Consultant to joint defendants in a case involving allegations that brand and generic manufacturers entered into co-promotion agreements amounting to reverse payment settlements of their Paragraph IV patent suits (Class Certification), 2015-2018.

Consultant to Celgene in a case alleging reverse payment settlement agreement with a generic manufacturer (Liability), 2018.

Consultant to Fresenius in a case relating to claims that Akorn, a company Fresenius had agreed to acquire, had suffered a material adverse effect. Evaluated first mover advantage in generic pharmaceutical industry and how delay of entry for generic manufacturers can lead to sustained reduced profits, 2018.

Consultant to a nuclear waste disposal company in a case relating to its proposed acquisition of a Class A waste facility, 2016-2017.

Consultant to Mutual Pharmaceuticals and King Pharmaceuticals in a case alleging that a licensing agreement was a disguised "stand down" payment leading to the delayed availability of generic metaxalone (Liability and Damages), 2014-2017.

Consultant to Teva on its proposed acquisition of Allergan Generics, 2015-2016.

Consultant to generic pharmaceutical manufacturer analysing the NPV of a product development and co-promotion agreement being reviewed by the FTC, 2014-2015

Consultant to generic pharmaceutical manufacturer analysing the net present value of profits flowing from a product development and co-promotion agreement being reviewed by the FTC, 2014-2015